Pharmaceutical care in the screening process of phase I oncohaematological clinical trials
The pharmacist's review of concomitant medication during the screening period in phase I clinical trials enables the detection of prohibited medication or relevant interactions, potentially avoiding screening failures and increasing the efficacy and safety of treatments.
Authors
- Rosa Rodríguez Mauriz (ORCID: https://orcid.org/0000-0003-3019-3483)
- Sandra Fontanals Martínez (ORCID: https://orcid.org/0000-0002-4450-2227)
- Toni Lozano-Andreu
- Monica González-Laguna
- Ana Clopés-Estela
- Lorena Santulario-Verdú
- Maria Emilia Miquel-Zurita
- Marina Millan-Coll
- Salomé Cañizares-Paz
- Maria Perayre-Badia
Institutions
- Bellvitge University Hospital (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Institut Català d'Oncologia (ES)
Publication Details
- Journal
- European Journal of Hospital Pharmacy
- Published
- 2024-08-13
- DOI
- https://doi.org/10.1136/ejhpharm-2024-004168
- Citations
- 2
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.69